INTRODUCTION
and allogeneic hematopoietic stem cell transplantation.
As a result of its previous classification and its shared features with MDS, CMML has often been combined with MDS in both epidemiologic and clinical studies, and few comparisons of the two diseases have been published. CMML was reported to have a worse 3-year survival than MDS using data from combined North American Association of Central Cancer Registries (NAACCR) and Surveillance Epidemiology and End
Results (SEER) databases (21% vs. 45%) (7) , as well as data on the Veterans Administration population (21% vs. 31%) (8). While treatments for both diseases are similar, data on efficacy of therapeutic agents in CMML are often extrapolated from studies in which CMML was combined with MDS. Also, while the International Prognostic Scoring System (IPSS) has an established role in determining the prognosis of MDS and in choosing the appropriate treatment (9), there is considerably more debate over the best tools for predicting prognosis in CMML (10). As a result, there may be greater uncertainty, and hence more heterogeneity, in therapeutic approaches to CMML.
In this study, using the SEER-Medicare database, we compared patient characteristics, treatments, progression to AML and progression-free survival (PFS, progression to AML or death) between CMML and MDS in older adults. Adjusted survival analyses allowed us to evaluate whether CMML is fundamentally a more aggressive disease than MDS, when controlling for patient characteristics and treatments received.
DESIGN AND METHODS

Data and Samples
Patients were identified from the SEER-Medicare database, which combines SEER data on incident cancers from 17 state and regional cancer registries with 
Patient characteristics
Sociodemographic characteristics included patient age, race, sex, census tractlevel median household income measured in quartile ranges, census tract-level measures of educational attainment, and diagnosis year.
MDS risk stratification
MDS patients were classified into lower-risk (RA, RARS, RCMD and 5qdel), RAEB, t-MDS, and NOS, using the SEER indicators. Although WHO categories do not fully match IPSS risk categories, their prognostic value has been documented (11).
Baseline health status
Patient health status included a series of indicators for baseline acute or chronic conditions, based on the presence of ICD-9 CM diagnostic codes in Medicare claims in the 12 months prior to the MDS diagnosis. To establish a diagnosis, we required one inpatient or two outpatient claims with the relevant diagnosis codes (with at least two claims 29 days apart but within 12 months, to limit inclusion of patients with rule-out diagnoses). The conditions that we identified included acute myocardial infarction (AMI), congestive heart failure (CHF) or other ischemic heart disease (IHD), cardiac arrhythmias, stroke, renal disease (acute and chronic renal disease, congenital, nephritic syndrome, nephrotic syndrome and dialysis), hepatitis or other liver disease, venous thromboembolic events (VTE), Alzheimer's dementia, and severe mental illness (depression, schizophrenia, bipolar disorder). We also created claims-based indicators associated with poor baseline performance status, including prior period hospitalization, skilled nursing facility (SNF) stay, nursing home admission, home oxygen, walking aids, and wheelchair (12). We included diagnoses of other cancers within the prior 5 years, and receipt of red blood cell (RBC) transfusions prior to diagnosis.
Treatments and outcome measurements
Treatments were identified in the period from diagnosis until death or censoring using presence of claims for specific inpatient diagnosis-related groups (DRGs), Rates of other baseline comorbidities were similar. Hospitalizations and wheelchair claims were less frequent in CMML patients, while other baseline healthcare use was similar (supplemental Table 1 ).
Treatments received are compared in Figure 1C ) (Supplemental Table 2 ). Adjusted estimates of PFS ( (data not shown). Increased age was associated with an increased risk of AML or death, while female sex, black race, and higher median household income were associated with decreased risk. Within the CMML cohort, increased age was associated with increased risk of AML or death, and higher median household income was associated with decreased risk.
DISCUSSION
To our knowledge, this work represents one of the first extensive comparisons of CMML and MDS at the population level, comparing characteristics, treatments and outcomes. We found that CMML was associated with a higher rate of progression to AML, more rapid progression, and shorter PFS and overall survival. Importantly, we found that more CMML patients did not receive treatment, compared to MDS patients.
Despite lower rates of treatments and small differences in patient characteristics, our adjusted analyses suggest that differences in biology between CMML and MDS may account for the substantially worse outcomes observed in the CMML cohort.
Differences in outcome for malignancies may be explained by the complex interplay between characteristics of the population affected, treatment availability and tolerability, and biology of the disease. We found that there were relatively few differences in baseline characteristics between the cohorts. MDS patients had a higher prevalence of several baseline conditions, including CHF/IHD, arrhythmias and liver disease, and a greater use of healthcare services associated with poor performance status. MDS patients have been reported to have increased prevalence of CHF and arrhythmias and greater age-adjusted risk of cardiac-related events compared to the general Medicare population (13), but it is unclear why we observed these differences in co-morbid conditions between MDS and CMML. Interestingly CMML patients had a higher male and white predominance, which where both independently associated with increased risk of progression to AML or death.
To our knowledge, our study provides the first comparison of treatment patterns for MDS and CMML patients. Overall, CMML patients were treated less frequently, compared to MDS patients. While our database does not provide much insight into biologic characteristics of the diseases that affect decisions about timing of treatment and use of different treatment modalities, there were relatively few differences in baseline health status and economic status, factors that can affect tolerability of treatment and access to treatment, respectively. Furthermore, differences in treatment patterns remained after adjusting for baseline characteristics, with MDS patients still more frequently receiving treatment of any sort. This suggests the need to reevaluate risk assessment and treatment algorithms used for CMML.
We observed relatively low rates for some treatments in both groups. However, the percentages of patients receiving this therapy were very low for both diseases, likely due to the older age of these patients and less frequent use of reducedintensity transplantation in the time period studied.
Our analysis showed that more CMML patients progressed to AML and overall survival was shorter, consistent with the results from prior population-based studies comparing MDS and CMML (7, 8) . In a unique extension, our adjusted analyses showed that differences in outcomes were not explained by patient characteristics that we could measure using the SEER-Medicare data, nor by the use of the most common treatments. While we observed different use rates for some of the less common treatments (for example, cytarabine and allogeneic stem cell transplantation), these differences would be unlikely to explain the large differences in outcomes between the two groups. Our results suggest that more aggressive biology, rather than differences in treatment, may account for the worse outcomes observed in our CMML cohort.
However, we acknowledge that there might be other patient characteristics that are important determinants of outcomes. Furthermore, while there is some information on treatment efficacy that is specific to CMML (16 -19), these patients are often combined with MDS patients in therapeutic clinical trials. Our findings also highlight the need for additional clinical trials to address efficacy of treatments specifically in CMML patients.
In our database, 35% of MDS patients were considered lower-risk (RA, RARS, RCMD, 5qdel), 15% were considered higher-risk (RAEB, t-MDS) and 50% were classified as MDS NOS. This distribution is similar to those in the NAACCR and SEER and the VA population studies (7, 8) . Given the high proportion of patients who have pathologic confirmation of their diagnosis, we expect that the high proportion assigned to MDS NOS reflects coding procedures that do not emphasize recording the risk group, rather than a failure to assess that information clinically. In the survival analysis that compared CMML to all MDS patients, our reference group reflects the pooled experience of the MDS cohort, many of whom are not assigned to a specific WHO category. When we addressed this limitation by comparing survival to lower risk MDS (RA) only, we found that CMML and higher-risk MDS (RAEB) have a similar increased risk of progression to AML or death. Further studies are needed to determine whether there are differences in outcomes between MDS and CMML patients with similar risk stratification. Analysis of differences in clinical parameters in a data set such as that used to develop the IPSS could be useful, but that specific data set excluded CMML patients with proliferative disease (9).
Our study has several potential limitations. Our study includes an elderly population, as only 2.5% and 4.17% of CMML and MDS patients, respectively, were younger than 65 years at diagnosis, and our findings cannot necessarily be extrapolated to younger patients. Also, population-based databases such as SEER-Medicare have limitations, including underreporting (20, 21), but we have no reason to think that underreporting would affect MDS differently than CMML. While, as previously noted, the lack of data on prognostic factors including cytopenias, blast percentages, and cytogenetic findings is an important limitation of the analysis, diagnosis was confirmed by histology in 87% of all cases, adding to the accuracy of this population based study.
Delays in treatment may lead to worse outcomes, but we did not analyze time from diagnosis to first treatment because of the lack of prognostic data, as we would have been unable to determine whether delays in starting treatment were appropriate. We also did not compare untreated CMML and MDS patients because we thought that there was likely to be treatment selection based on patient characteristics that were not captured in our database. Furthermore, given that less is known about determinants of treatment efficacy specific to CMML, we were concerned that the unobserved factors may differ for the two diseases. As a result, we did not focus on the estimated effects of treatments, but noted that their inclusion did not affect the estimated effect of CMML relative to MDS on survival. Comparison of patients with other MDS/MPN diagnoses would also have been of interest, but numbers of cases did not allow for meaningful comparisons.
Even with the above-noted limitations, our paper represents a unique comparison of baseline characteristics, treatments and outcomes between CMML and MDS patients. Importantly we have observed that CMML patients were less frequently treated, but also had more frequent progression to AML and shorter survival even after controlling for baseline characteristics and treatments received. Our data support the continued need to study biological differences between MDS and CMML, evaluate the prognostic scoring systems and treatment algorithms used in CMML, further assess the efficacy of existing therapies and develop new treatments for CMML.
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